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Background: Current guidelines recommend 1 year of dual antiplatelet (DAPT) after implantation of drug eluting stents (DES). However, 
recent clinical trials, including one published just a few months ago, have challenged these recommendations by suggesting that a shorter 
duration of DAPT may be adequate for procedures using second-generation DES. In addition, the findings of individual trials have been 
scrutinized due to their small sample size and lack of statistical power. We conducted an updated meta-analysis of randomized trials to 
assess the efficacy and safety of ≤ 6 months versus ≥ 12 months DAPT after implantation of DES.
methods: Relevant randomized trials were included in the analysis. The pooled risk ratio (RR) was calculated using random-effect models.
results: Five trials involving 10,048 patients were included; 5009 patients were randomized to shorter and 5039 patients to longer duration 
DAPT. There were no differences in the risk of all-cause mortality (RR 0.94; 95% CI, 0.72−1.22; P = 0.63), cardiac death (0.94; 0.69−1.29; 
P = 0.72), myocardial infarction (1.14; 0.89−1.47; P = 0.30), or stent thrombosis (1.17; 0.73−1.89; P = 0.52) between short-term and long-
term DAPT. Short-term DAPT was associated with a decreased risk of major bleeding (0.53; 0.33−0.89; P = 0.011).
Conclusion: Extended-duration DAPT was not associated with cardiovascular or mortality benefits after implantation of DES, although the 
risk of major bleeding was significantly lower with shorter duration of therapy.
 
